EVOLENT HEALTH INC - A (EVH) Stock Fundamental Analysis
NYSE:EVH - New York Stock Exchange, Inc. - US30050B1017 - Common Stock - Currency: USD
Overall EVH gets a fundamental rating of 4 out of 10. We evaluated EVH against 39 industry peers in the Health Care Technology industry. Both the profitability and financial health of EVH have multiple concerns. EVH is growing strongly while it also seems undervalued. This is an interesting combination
1. Profitability
1.1 Basic Checks
In the past year EVH was profitable.
EVH had a positive operating cash flow in the past year.
EVH had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: EVH reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of -4.17%, EVH is doing good in the industry, outperforming 78.38% of the companies in the same industry.
The Return On Equity of EVH (-8.50%) is better than 78.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -8.5% | ||
| ROIC | N/A |
ROA(3y)-3%
ROA(5y)-10.71%
ROE(3y)-6.36%
ROE(5y)-21.15%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 15.96%, EVH is doing worse than 83.78% of the companies in the same industry.
In the last couple of years the Gross Margin of EVH has declined.
The Profit Margin and Operating Margin are not available for EVH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.68%
GM growth 5Y-13.25%
2. Health
2.1 Basic Checks
EVH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVH has been increased compared to 1 year ago.
The number of shares outstanding for EVH has been increased compared to 5 years ago.
Compared to 1 year ago, EVH has an improved debt to assets ratio.
2.2 Solvency
EVH has an Altman-Z score of 1.12. This is a bad value and indicates that EVH is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EVH (1.12) is comparable to the rest of the industry.
The Debt to FCF ratio of EVH is 5.47, which is a neutral value as it means it would take EVH, 5.47 years of fcf income to pay off all of its debts.
EVH's Debt to FCF ratio of 5.47 is fine compared to the rest of the industry. EVH outperforms 67.57% of its industry peers.
A Debt/Equity ratio of 0.49 indicates that EVH is not too dependend on debt financing.
EVH's Debt to Equity ratio of 0.49 is on the low side compared to the rest of the industry. EVH is outperformed by 67.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 5.47 | ||
| Altman-Z | 1.12 |
ROIC/WACCN/A
WACC10.22%
2.3 Liquidity
EVH has a Current Ratio of 1.04. This is a normal value and indicates that EVH is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of EVH (1.04) is worse than 64.86% of its industry peers.
A Quick Ratio of 1.04 indicates that EVH should not have too much problems paying its short term obligations.
EVH has a worse Quick ratio (1.04) than 64.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
EVH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.33%, which is quite impressive.
Looking at the last year, EVH shows a very strong growth in Revenue. The Revenue has grown by 37.65%.
Measured over the past years, EVH shows a very strong growth in Revenue. The Revenue has been growing by 25.65% on average per year.
EPS 1Y (TTM)21.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.67%
Revenue 1Y (TTM)37.65%
Revenue growth 3Y28.54%
Revenue growth 5Y25.65%
Sales Q2Q%21.6%
3.2 Future
Based on estimates for the next years, EVH will show a very strong growth in Earnings Per Share. The EPS will grow by 20.02% on average per year.
Based on estimates for the next years, EVH will show a quite strong growth in Revenue. The Revenue will grow by 19.05% on average per year.
EPS Next Y-15.27%
EPS Next 2Y6.9%
EPS Next 3Y13.3%
EPS Next 5Y20.02%
Revenue Next Year31.22%
Revenue Next 2Y18.81%
Revenue Next 3Y17.03%
Revenue Next 5Y19.06%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
EVH is valuated reasonably with a Price/Earnings ratio of 11.44.
EVH's Price/Earnings ratio is rather cheap when compared to the industry. EVH is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.28. EVH is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 10.35, the valuation of EVH can be described as very reasonable.
100.00% of the companies in the same industry are more expensive than EVH, based on the Price/Forward Earnings ratio.
EVH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 91.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.44 | ||
| Fwd PE | 10.35 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EVH is valued cheaper than 83.78% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EVH indicates a rather cheap valuation: EVH is cheaper than 86.49% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.07 | ||
| EV/EBITDA | 16.54 |
4.3 Compensation for Growth
EVH's earnings are expected to grow with 13.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.9%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
No dividends for EVH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EVOLENT HEALTH INC - A
NYSE:EVH (1/29/2025, 8:21:44 PM)
After market: 10.41 0 (0%)10.41
-0.01 (-0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners114.02%
Inst Owner Change-0.04%
Ins Owners1.26%
Ins Owner Change-0.62%
Market Cap1.21B
Analysts84.21
Price Target25.59 (145.82%)
Short Float %9.06%
Short Ratio3.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.48%
Min EPS beat(2)-88.41%
Max EPS beat(2)17.44%
EPS beat(4)3
Avg EPS beat(4)5.4%
Min EPS beat(4)-88.41%
Max EPS beat(4)52.95%
EPS beat(8)6
Avg EPS beat(8)42.57%
EPS beat(12)10
Avg EPS beat(12)644.04%
EPS beat(16)14
Avg EPS beat(16)496.66%
Revenue beat(2)1
Avg Revenue beat(2)-0.61%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)0.68%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-1.9%
Max Revenue beat(4)5.41%
Revenue beat(8)5
Avg Revenue beat(8)0.61%
Revenue beat(12)8
Avg Revenue beat(12)1.4%
Revenue beat(16)10
Avg Revenue beat(16)0.58%
PT rev (1m)-0.24%
PT rev (3m)-39.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-85.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-45.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.54%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.44 | ||
| Fwd PE | 10.35 | ||
| P/S | 0.49 | ||
| P/FCF | 11.07 | ||
| P/OCF | 9.03 | ||
| P/B | 0.99 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.54 |
EPS(TTM)0.91
EY8.74%
EPS(NY)1.01
Fwd EY9.66%
FCF(TTM)0.94
FCFY9.03%
OCF(TTM)1.15
OCFY11.07%
SpS21.14
BVpS10.52
TBVpS-5.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -8.5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.96% | ||
| FCFM | 4.45% |
ROA(3y)-3%
ROA(5y)-10.71%
ROE(3y)-6.36%
ROE(5y)-21.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.68%
GM growth 5Y-13.25%
F-Score6
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 5.47 | ||
| Debt/EBITDA | 5.78 | ||
| Cap/Depr | 20.89% | ||
| Cap/Sales | 1.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 129.46% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z | 1.12 |
F-Score6
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)45.21%
Cap/Depr(5y)49.12%
Cap/Sales(3y)2.58%
Cap/Sales(5y)3.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.67%
EPS Next Y-15.27%
EPS Next 2Y6.9%
EPS Next 3Y13.3%
EPS Next 5Y20.02%
Revenue 1Y (TTM)37.65%
Revenue growth 3Y28.54%
Revenue growth 5Y25.65%
Sales Q2Q%21.6%
Revenue Next Year31.22%
Revenue Next 2Y18.81%
Revenue Next 3Y17.03%
Revenue Next 5Y19.06%
EBIT growth 1Y-146.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.01%
EBIT Next 3Y27.56%
EBIT Next 5Y26.64%
FCF growth 1Y545.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y592.31%
OCF growth 3YN/A
OCF growth 5YN/A